Chondroitin sulfate market

On the whole, the raw material industry of Chondroitin sulfate powder has a small market space, low added value, and many production enterprises, so it is difficult to form a large enterprise, and the investment value is small. Downstream health products and drugs have a certain industry scale, but product homogenization is severe, competition is fierce, and there are not many opportunities to grow and strengthen. At present, there are four companies on the A-share and Third Board that have related businesses. When A-shareholders Cheng Pharmaceutical and Thomson Beijian went public, their sulfuric acid cartilage business was not their main business; The two companies on the third board, Haiyu Bio and Huiwen Bio Chondroitin sulfate, have small business scale. With the exception of Haiyu Biology, other companies' Chondroitin sulfate business income accounted for a small proportion of the total income.